solid growth unfavor
neutral rather mix sale higher valu ad
franchis wound ostomi under-perform growth
expect nevertheless upgrad sales/ebit/ep
averag mainli benign fx effect
roll dcf arriv upgrad target price previous
consid risk/reward stay neutral
solid growth unfavor mix underli
growth y/i convatec exceed consensu growth
expect respect encourag
howev growth perform key franchis rather
unsatisfactori ostomi manag state estim
normal growth rate report underli sale
declin still clearli relev market growth
rate estim even month post
ipo execut ostomi growth strategi underli sale
growth rather driven one-tim growth bolu infus
devic key custom restock infus set inventori
contin critic two franchis estim
group averag margin slow growth core
busi see major risk manag need use
product improv driven cost save reinvest oper
 distribut etc remain competit current valuat
admittedli reflect risk attract risk/reward
opportun european healthcar sector view
catalyst risk earn expect august
valuat valu convatec per share use dcf
methodolog assum averag revenu growth adj
ebit margin
valuat metric
price month
price rel chart measur perform
ftse close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
mariu zoican univers toronto rotman school manag may
convatec chronic care medic devic compani lead
posit attract advanc wound ostomi care market
price may rate neutral target price analyst christoph gretler
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
sky scenario assum greater market share gain
convatec ostomi franchis current expect growth
howev compani legaci technolog posit combin
success execut could see grow underli
forecast period
hand grey sky scenario assum
compani turnaround strategi ostomi may fail could lose
market share grow flattish slightli neg rate
current assumpt
price rel chart measur perform ftse
close
spot exchang rate
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
mariu zoican univers toronto rotman school manag may
figur varianc cs estim consensu
us million unless otherwis state
varianc consensu
favour fx rate support contribut woodburi
hold medic llc
support continu growth aquacel foam rang
impact suppli constraint prevail good
momentum convex product introduc good progress
fulfil backord moldabl product
driven hdg sale gentlecathtm contribut
woodburi hold medic combin
divest symbiu medic respiratori busi
figur cs estim chang
us million unless otherwis state
sale
ebit
mariu zoican univers toronto rotman school manag discount free cash flow
us million unless otherwis state
 depreci amortis acquir
 tax ebit
depreci amortis acquir
 chang work capit wc
 chang asset
 invest intang acquisit
equiti valu per share penc
work capit sale
increment capital-expenditure sale
weight averag cost capit
mariu zoican univers toronto rotman school manag
us million unless otherwis mention
sale growth local currenc
contin critic
ebitda busi line cs estim
mariu zoican univers toronto rotman school manag figur convatec incom statement
us million unless otherwis state
non recur oper result
report ep us
cs adj ep us
good sold report
amort intang asset
restructur non-recur cost
good sold adjust
sell market expens report
sale
restructur non-recur cost
sell market expens adjust
sale
gener admin expens report
sale
amort intang
restructur non-recur cost
gener admin expens adjust
sale
sale
restructur non-recur cost
sale
gross fix asset
gross invest fix asset
depreci
sale
gross invest intang
interest charg gross debt
currenc gain loss
loss financi asset
tax rate report pbt
tax rate adjust pbt
mariu zoican univers toronto rotman school manag may
compani mention price
